Thomson Medical Group Full Year 2024 Earnings: Misses Expectations

editorial-team@simplywallst.com (Simply Wall St)

Thu, Aug 29, 2024, 4:14 PM 1 min read

Thomson Medical Group (SGX:A50) Full Year 2024 Results

Key Financial Results

Revenue: S$382.7m (up 6.1% from FY 2023).
Net income: S$15.4m (down 58% from FY 2023).
Profit margin: 4.0% (down from 10% in FY 2023). The decrease in margin was driven by higher expenses.
EPS: S$0.001 (in line with FY 2023).

revenue-and-expenses-breakdown — SGX:A50 Revenue and Expenses Breakdown August 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Thomson Medical Group Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 13%. Earnings per share (EPS) also missed analyst estimates by 42%.

The primary driver behind last 12 months revenue was the Singapore segment contributing a total revenue of S$200.2m (52% of total revenue). Notably, cost of sales worth S$197.0m amounted to 51% of total revenue thereby underscoring the impact on earnings.Explore how A50's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 6.9% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare industry in Asia.

Performance of the market in Singapore.

The company's shares are down 2.0% from a week ago.

Risk Analysis

It is worth noting though that we have found 2 warning signs for Thomson Medical Group (1 makes us a bit uncomfortable!) that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.